RABGGTB: A Potential Drug Target and Biomarker for Geranylgeranyl Transferase Type II Subunit Beta

Target Name: RABGGTB

NCBI ID: G5876

RABGGTB

RABGGTB: A Potential Drug Target and Biomarker for Geranylgeranyl Transferase Type II Subunit Beta

Geranylgeranyl transferase type II subunit beta (RABGGTB) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and peripheral tissues. It plays a critical role in the metabolism of geranylgeranyl, a key metabolite of the plant hormone 2-methylbutane. RABGGTB is also involved in the regulation of cellular processes that are important for tissue growth and development, as well as the development and progression of various diseases.

Due to its involvement in multiple cellular processes, RABGGTB has been identified as a potential drug target. By inhibiting the activity of RABGGTB, researchers can potentially interfere with the signaling pathways that are responsible for the growth, development, and function of various tissues. This can lead to a range of potential therapeutic benefits, including the treatment of various diseases.

In addition to its potential as a drug target, RABGGTB has also been identified as a potential biomarker for a number of diseases. The production of RABGGTB is regulated by a complex of enzymes, including the enzymes GAR, FAS-1, and UDP-glucuronate transporter (UGT). Therefore, the levels of RABGGTB in cells can be affected by a variety of factors, including the levels of these enzymes.

One of the potential applications of RABGGTB as a biomarker is its potential to serve as a diagnostic marker for a variety of diseases. For example, RABGGTB has been shown to be elevated in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurological disorders. Additionally, RABGGTB has been shown to be elevated in the blood of individuals with certain types of cancer, which may serve as a potential biomarker for cancer diagnosis and treatment.

Another potential application of RABGGTB as a biomarker is its potential to serve as a target for therapeutic intervention. For example, RABGGTB has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting RABGGTB with drugs or other therapeutic agents may be a promising strategy for the treatment of these diseases.

In conclusion, RABGGTB is a protein that is involved in a variety of cellular processes throughout the body. Its involvement in these processes makes it a potential drug target, as well as a potential biomarker for a variety of diseases. Further research is needed to fully understand the role of RABGGTB in cellular processes and its potential as a therapeutic target or biomarker.

Protein Name: Rab Geranylgeranyltransferase Subunit Beta

Functions: Catalyzes the transfer of a geranylgeranyl moiety from geranylgeranyl diphosphate to both cysteines of Rab proteins with the C-terminal sequence -XXCC, -XCXC and -CCXX, such as RAB1A, RAB3A, RAB5A and RAB7A

The "RABGGTB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RABGGTB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets